Last reviewed · How we verify

Bicillin C-R — Competitive Intelligence Brief

Bicillin C-R (Penicillin G Benzathine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-lactam antibiotic.

marketed Beta-lactam antibiotic Cell-wall peptidoglycan biosynthesis Small molecule Live · refreshed every 30 min

Target snapshot

Bicillin C-R (Penicillin G Benzathine) — Pfizer. Penicillin G inhibits bacterial cell-wall peptidoglycan biosynthesis, rendering the cell wall osmotically unstable.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Bicillin C-R TARGET Penicillin G Benzathine Pfizer marketed Beta-lactam antibiotic Cell-wall peptidoglycan biosynthesis 1952-01-01
Bicillin C-R Penicillin G Benzathine Pfizer marketed Beta-lactam antibiotic Cell-wall peptidoglycan biosynthesis 1952-01-01
Bicillin C-R Penicillin G Benzathine Pfizer Inc. marketed Beta-lactam antibiotic Cell-wall peptidoglycan biosynthesis
Amoxil amoxicillin Generic (originally Beecham/GSK) marketed Aminopenicillin (Beta-lactam antibiotic) 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C 1972-01-01
Vonoprazan-Amoxicillin with Berberine Vonoprazan-Amoxicillin with Berberine Nanjing First Hospital, Nanjing Medical University marketed H. pylori eradication therapy (combination: proton pump inhibitor alternative + beta-lactam antibiotic + herbal antimicrobial) H+/K+-ATPase (vonoprazan); bacterial cell wall (amoxicillin); multiple H. pylori targets (berberine)
cefoperazone sodium and sulbactam sodium cefoperazone sodium and sulbactam sodium Yung Shin Pharm. Ind. Co., Ltd. marketed Beta-lactam antibiotic with beta-lactamase inhibitor Bacterial penicillin-binding proteins; beta-lactamases
Vonoprazan+amoxicillin 14 days Vonoprazan+amoxicillin 14 days Xijing Hospital of Digestive Diseases marketed Potassium-competitive acid blocker + beta-lactam antibiotic combination H+/K+-ATPase (vonoprazan); bacterial cell wall peptidoglycan (amoxicillin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (Beta-lactam antibiotic class)

  1. Pfizer · 2 drugs in this class
  2. Bayer · 1 drug in this class
  3. Belén Retamal-Valdes · 1 drug in this class
  4. Benova (Tianjin) Innovative medicine Research Co., Ltd. · 1 drug in this class
  5. Esraa Salah Mohamed Abdallah Eladl · 1 drug in this class
  6. Incheon St.Mary's Hospital · 1 drug in this class
  7. International Maternal Pediatric Adolescent AIDS Clinical Trials Group · 1 drug in this class
  8. KEMRI-Wellcome Trust Collaborative Research Program · 1 drug in this class
  9. National Taiwan University Hospital · 1 drug in this class
  10. Pfizer Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bicillin C-R — Competitive Intelligence Brief. https://druglandscape.com/ci/bicillin-l-a. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: